Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.
Clin. Transplant. 20, 80-84 (2006)
Non-compliance in solid transplantation recipients is a major factor in acute graft rejection, which influences patient survival. Nowadays, tacrolimus is one of the most widely used immunosuppressant agents together with cyclosporine following kidney and liver transplantation with a standardized twice-daily dosing regimen. To improve the patients' compliance to the prescribed immunosuppressive therapy, FK506E (MR4), a modified release (MR) oral dosage form of tacrolimus has been developed for a once-daily dosing regimen. This report reviews the most recent results of clinical trials with MR tacrolimus after kidney and liver transplantation.
Impact Factor
Scopus SNIP
Altmetric
0.000
0.000
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Sprache
englisch
Veröffentlichungsjahr
2006
HGF-Berichtsjahr
0
ISSN (print) / ISBN
0902-0063
e-ISSN
1399-0012
Zeitschrift
Clinical Transplantation
Quellenangaben
Band: 20,
Seiten: 80-84
Verlag
Wiley
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Pancreatic Islet Research (IPI)
PubMed ID
17100706
Erfassungsdatum
2006-12-31